ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2

ClinicalTrials.gov ID: NCT06555783

Public ClinicalTrials.gov record NCT06555783. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2

Study identification

NCT ID
NCT06555783
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Alkermes, Inc.
Industry
Enrollment
93 participants

Conditions and interventions

Interventions

  • ALKS 2680 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 25, 2024
Primary completion
Nov 10, 2025
Completion
Nov 20, 2025
Last update posted
Feb 26, 2026

2024 – 2025

United States locations

U.S. sites
33
U.S. states
16
U.S. cities
32
Facility City State ZIP Site status
Alkermes Investigator Site Little Rock Arkansas 72211
Alkermes Investigator Site Los Angeles California 90025
Alkermes Investigator Site Redwood City California 94063
Alkermes Investigator Site San Francisco California 94143
Alkermes Investigator Site Santa Ana California 92705
Alkermes Investigational Site Aurora Colorado 80045
Alkermes Investigator Site Colorado Springs Colorado 80918
Alkermes Investigator Site Brandon Florida 33511
Alkermes Investigator Site Miami Florida 33176
Alkermes Investigator Site Winter Park Florida 32789
Alkermes Investigator Site Atlanta Georgia 30328
Alkermes Investigational Site Macon Georgia 31210
Alkermes Investigator Site Stockbridge Georgia 30281
Alkermes Investigational Site Peoria Illinois 61637
Alkermes Investigator Site Lansing Michigan 48911
Alkermes Investigator Site Sterling Heights Michigan 48314
Alkermes Investigator Site Lincoln Nebraska 68506
Alkermes Investigator Site Middletown New Jersey 07748
Alkermes Investigator Site Denver North Carolina 28037
Alkermes Investigator Site Huntersville North Carolina 28078
Alkermes Investigator Site Canton Ohio 44718
Alkermes Investigator Site Cincinnati Ohio 45212
Alkermes Investigator Site Cincinnati Ohio 45245
Alkermes Investigational Site Cleveland Ohio 44195
Alkermes Investigator Site Abington Pennsylvania 19001
Alkermes Investigational Site Philadelphia Pennsylvania 19107
Alkermes Investigator Site Wyomissing Pennsylvania 19610
Alkermes Investigator Site Columbia South Carolina 29201
Alkermes Investigator Site Cordova Tennessee 38108
Alkermes Investigator Site Austin Texas 78731
Alkermes Investigator Site San Antonio Texas 78229
Alkermes Investigational Site Sugar Land Texas 77478
Alkermes Investigational Site Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06555783, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 26, 2026 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06555783 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →